Scott Washko
President and CEO
Replay available
Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2023 earnings conference call, held 2024-02-26. Replay captured from the company's public earnings webcast.

President and CEO
Chief Financial Officer
Chief Research and Development Officer
Analyst, Jefferies
Analyst, Citigroup
Analyst, TD Cohen
Analyst, Bank of America
Analyst, Lurink Partners
Analyst, Morgan Stanley
Analyst, Barclays
Analyst, Stiefel (on behalf of Ben Burnett)
Analyst, Goldman Sachs (on behalf of Andrea Tan)
Analyst, Wells Fargo Securities
Welcome to the Faith Therapeutics fourth quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. This call is being webcast live on the investors section of Faith's website at faiththerapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Washko, president and CEO of Faith Therapeutics. Thank you. Good afternoon and thanks everyone for joining us for the Faith Therapeutics fourth quarter 2023 financial results call. Shortly after 4 p.m. Eastern time today, we issued a press release with these results, which can be found on the investor section of our website under press releases. In addition, our form 10K for the year ended December 31, 2023 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the company's earnings press release issued after the close of market today, as well as the risk factors included in our Form 10-K for the year ended December 31, 2023 that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, Fait...